Protective effect of edaravone against Alzheimer's disease-relevant insults in neuroblastoma N2a cells

Neuroscience Letters

Volumn 531, Issue 2, 2012, Pages 160-165

  Yan, Yufang ^a   Gong, Kai ^a   Ma, Tuo ^a   Zhang, Lihai ^b   Zhao, Nanming ^a   Zhang, Xiufang ^a   Tang, Peifu ^b   Gong, Yandao ^a  

^a TSINGHUA UNIVERSITY   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Alzheimer's disease; Apoptosis; Edaravone; Oxidative stress

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; CASPASE 3; CYTOCHROME C; NORPHENAZONE; PROTEIN BAX; PROTEIN BCL 2;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL CELL CULTURE; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CELL VIABILITY; ENZYME INHIBITION; IN VITRO STUDY; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NEUROBLASTOMA CELL; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN ANALYSIS;

ALZHEIMER DISEASE; ANIMALS; ANTIPYRINE; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FREE RADICAL SCAVENGERS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; NEUROBLASTOMA; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS;

EID: 84870441984     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2012.10.043     Document Type: Article

References (18)

1. Adams J.M., Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 1998, 281:1322-1326.
2. Amemiya S., Kamiya T., Nito C., Inaba T., Kato K., Ueda M., Shimazaki K., Katayama Y. Anti-apoptotic and neuroprotective effects of edaravone following transient focal ischemia in rats. European Journal of Pharmacology 2005, 516:125-130.
3. De Strooper B. Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process. Physiological Reviews 2010, 90:465-494.
4. Green D.R., Reed J.C. Mitochondria and apoptosis. Science 1998, 281:1309-1312.
5. Hensley K., Carney J.M., Mattson M.P., Aksenova M.V., Harris M.E., Wu J.F., Floyd R.A., Butterfield D.A. A model for beta-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer disease. Proceedings of the National Academy of Sciences of the United States of America 1994, 91:3270-3274.
6. Itoh T., Satou T., Nishida S., Tsubaki M., Imano M., Hashimoto S., Ito H. Edaravone protects against apoptotic neuronal cell death and improves cerebral function after traumatic brain injury in rats. Neurochemical Research 2010, 35:348-355.
7. Kawai H., Nakai H., Suga M., Yuki S., Watanabe T., Saito K.I. Effects of a novel free radical scavenger, MCI-186, on ischemic brain damage in the rat distal middle cerebral artery occlusion model. Journal of Pharmacology and Experimental Therapeutics 1997, 281:921-927.
8. Luo Y., Smith J.V., Paramasivam V., Burdick A., Curry K.J., Buford J.P., Khan I., Netzer W.J., Xu H., Butko P. Inhibition of amyloid-beta aggregation and caspase-3 activation by the Ginkgo biloba extract EGb761. Proceedings of the National Academy of Sciences of the United States of America 2002, 99:12197-12202.
9. Ramalho R.M., Borralho P.M., Castro R.E., Solá S., Steer C.J., Rodrigues C.M. Tauroursodeoxycholic acid modulates p53-mediated apoptosis in Alzheimer's disease mutant neuroblastoma cells. Journal of Neurochemistry 2006, 98:1610-1618.
10. Saelens X., Festjens N., Vande Walle L., van Gurp M., van Loo G., Vandenabeele P. Toxic proteins released from mitochondria in cell death. Oncogene 2004, 23:2861-2874.
11. Shen C., Chen Y., Liu H., Zhang K., Zhang T., Lin A., Jing N. Hydrogen peroxide promotes Abeta production through JNK-dependent activation of gamma-secretase. Journal of Biological Chemistry 2008, 283:17721-17730.
12. Sponne I., Fifre A., Drouet B., Klein C., Koziel V., Pinçon-Raymond M., Olivier J.L., Chambaz J., Pillot T. Apoptotic neuronal cell death induced by the non-fibrillar amyloid-beta peptide proceeds through an early reactive oxygen species-dependent cytoskeleton perturbation. Journal of Biological Chemistry 2003, 278:3437-3445.
13. Suen D.F., Norris K.L., Youle R.J. Mitochondrial dynamics and apoptosis. Genes & Development 2008, 22:1577-1590.
14. Takahashi R. Edaravone in ALS. Experimental Neurology 2009, 217:235-236.
15. Unkila M., McColl K.S., Thomenius M.J., Heiskanen K., Distelhorst C.W. Unreliability of the cytochrome c-enhanced green fluorescent fusion protein as a marker of cytochrome c release in cells that overexpress Bcl-2. Journal of Biological Chemistry 2001, 276:39132-39137.
16. Watanabe T., Yuki S., Egawa M., Nishi H. Protective effects of MCI-186 on cerebral ischemia: possible involvement of free radical scavenging and antioxidant actions. Journal of Pharmacology and Experimental Therapeutics 1994, 268:1597-1604.
17. Xiong N., Xiong J., Khare G., Chen C., Huang J., Zhao Y., Zhang Z., Qiao X., Feng Y., Reesaul H., Zhang Y., Sun S., Lin Z., Wang T. Edaravone guards dopamine neurons in a rotenone model for Parkinson's disease. PLoS ONE 2011, 6:e20677.
18. Yagi H., Horinaka S., Matsuoka H. Edaravone prevented deteriorated cardiac function after myocardial ischemia-reperfusion via inhibiting lipid peroxidation in rat. Journal of Cardiovascular Pharmacology 2005, 46:46-51.